CF
MDGL icon

Corebridge Financial’s Madrigal Pharmaceuticals MDGL Stock Holding History

Corebridge Financial’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,807
Closed -$2.92M – 1630
2025
Q1 		$2.92M Sell
8,807
-131
-1% -$43K 0.02% 857
2024
Q4 		$2.76M Sell
8,938
-442
-5% -$124K 0.01% 904
2024
Q3 		$1.99M Sell
9,380
-58
-0.6% -$14.8K 0.01% 1041
2024
Q2 		$2.64M Buy
+9,438
New +$2.25M 0.01% 917

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Corebridge Financial's MDGL Position: Q2 2025 in Review

Corebridge Financial sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2025, closing a stake of 8,807 shares — an estimated $2.92M sold.

Corebridge Financial first reported a position in MDGL in Q2 2024 and held it in 4 quarters. The position peaked at $2.92M in Q1 2025. 305 funds tracked by Wall St. Rank hold MDGL as of Q2 2025.

  • Corebridge Financial reported no remaining Madrigal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 8,807 Madrigal Pharmaceuticals shares in Q2 2025, an estimated $2.92M.
  • Corebridge Financial first reported a position in Madrigal Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Madrigal Pharmaceuticals position peaked at $2.92M in Q1 2025.
  • 305 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.